

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redefine- PHine)

NCT06839235

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Arbor Biotechnologies
Enrollment	23 participants

Key Eligibility Criteria

Inclusion (7)

- Documentation of PH1 as determined by genetic analysis confirming pathogenic mutations in the alanine-glyoxylate aminotransferase (AGXT) gene (valid historical laboratory data will be reviewed and approved by the Sponsor)
- Age at time of signing the informed consent/assent form:
- Part A: e18 years to d64 years
- Part B: e6 years to <18 years
- hour UOx e0.7 mmol/24 hours/1.73 m²
- ... and 2 more (see full listing online)

Exclusion (5)

- Confirmed diagnosis of primary hyperoxaluria type 2 or type 3
- History of a liver, kidney or combined liver/kidney transplant
- Currently on dialysis
- Participant has previously used (within past 24 months) or is currently receiving an approved or investigational urinary oxalate lowering RNA interference (RNAi) or siRNA therapy
- Female participants who are pregnant or breastfeeding (or are planning either during the first 12 months)

Locations (7 total)

Mayo Clinic, Rochester, Minnesota, United States
Nucleus Network, Saint Paul, Minnesota, United States
Hospices Civils de Lyon- Hôpital Femmes Mères Enfants, Lyon, France
... and 4 more locations